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ABSTRACT 
 
BACKGROUND 
Cardiovascular Magnetic Resonance (CMR) is the gold-standard technique for assessment of ventricular 
function. Although left ventricular (LV) volumes and ejection fraction are strong predictors of outcome in 
dilated cardiomyopathy (DCM), there are limited data regarding the prognostic significance of right 
ventricular (RV) systolic dysfunction (RVSD). We investigated whether CMR assessment of RV function 
has prognostic value in DCM. 
 
METHODS AND RESULTS 
We prospectively studied 250 consecutive DCM patients using CMR. RVSD, defined by RV ejection 
fraction ≤45%, was present in 86 (34%) patients. During a median follow-up period of 6.8 years, there 
were 52 deaths and 7 patients underwent cardiac transplantation . The primary end point of all-cause 
mortality or cardiac transplantation was reached by 42 of 86 patients with RVSD and 17 of 164 patients 
without RVSD (49% vs. 10%; hazard ratio [HR], 5.90; 95% confidence interval [CI], 3.35 to 10.37; 
P<0.001). On multivariable analysis, RVSD remained a significant independent predictor of the primary 
end point (HR, 3.90; 95% CI, 2.16 to 7.04; P<0.001), as well as secondary outcomes of cardiovascular 
mortality or cardiac transplantation (HR, 3.35; 95% CI, 1.76 to 6.39; P<0.001), and heart failure (HF) 
death, HF hospitalization or cardiac transplantation (HR, 2.70; 95% CI, 1.32 to 5.51; P=0.006). 
Assessment of RVSD improved risk stratification for all-cause mortality or cardiac transplantation (net 
reclassification improvement, 0.31; 95% CI 0.10 to 0.53; P=0.001). 
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CONCLUSIONS 
RVSD is a powerful, independent predictor of transplant-free survival and adverse HF outcomes in DCM. 
CMR assessment of RV function is important in the evaluation and risk stratification of DCM patients. 
 
Key Words: cardiomyopathy, heart failure, magnetic resonance imaging, prognosis, right ventricular 
function 
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INTRODUCTION 
Studies in heart failure (HF) generally focus on functional assessment of the left ventricle. Conversely the 
right ventricle has received far less attention in the evaluation of HF patients.1-4 Much of this neglect 
stems from the fact that the right ventricle has complex structural and physiological properties which pose 
challenges for assessment of its morphology and function.2, 4, 5 However, adverse remodelling of the right 
ventricle is an important component of the HF syndrome. In particular, previous studies in HF cohorts of 
mixed etiology have suggested that right ventricular (RV) ejection fraction (RVEF), assessed by 
radionuclide or thermodilution techniques, may be a major determinant of exercise capacity and 
outcome.6-9 Consequently there is growing interest regarding the clinical relevance of RV functional 
assessment in the HF population.1, 3, 4 
Dilated cardiomyopathy (DCM) is the second most common etiology of HF after coronary artery 
disease,10 and remains the leading indication for cardiac transplantation.11 Although the exact prevalence 
is poorly defined, RV systolic dysfunction (RVSD) has been reported in as many as 65% of DCM 
patients,12 suggesting that DCM is frequently a biventricular disease. The potential prognostic impact of 
RV impairment in DCM has been highlighted by two small studies which suggested that RVSD is an 
independent predictor of survival.13, 14  
To date, the few studies evaluating RV systolic performance in DCM have either utilised thermodilution 
or contrast ventriculography to estimate RVEF.12-14 Such techniques are invasive with the result that their 
clinical application is limited. In contrast, cardiovascular magnetic resonance (CMR) allows non-invasive 
measurement of RVEF with high accuracy and reproducibility.15-19 Despite the fact that CMR is now 
firmly established as the gold standard for RV assessment,4, 5, 20 CMR data regarding the prevalence and 
prognostic implications of RVSD in DCM is lacking. We therefore sought to prospectively evaluate the 
prevalence and prognostic significance of RVSD, as assessed by CMR, in a broad spectrum of DCM 
patients. 
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METHODS 
Patients 
The study prospectively enrolled 250 consecutive patients with DCM (236 outpatients, 14 inpatients) who 
were referred for CMR by their treating cardiologist between November 2000 and March 2006. The 
diagnosis of DCM was made according to World Health Organization/International Society and 
Federation of Cardiology criteria.21 All patients had left ventricular (LV) ejection fraction (LVEF) < 50% 
on transthoracic echocardiography of at least 6 months duration with no evidence of significant coronary 
artery disease (>50% diameter luminal stenosis in one or more epicardial vessels, history of myocardial 
infarction or coronary revascularization, or infarct pattern of late gadolinium enhancement). Prior to 
inclusion the diagnosis of DCM was confirmed by CMR, on the basis of increased LV end-diastolic 
volume indexed to body surface area (LVEDV index) and reduced LVEF, compared to published 
reference ranges normalized for age and gender.22 Patients with a history of chronic lung disease, previous 
pulmonary embolism or idiopathic pulmonary hypertension were excluded. Additional exclusion criteria 
were hypertensive heart disease, tachycardia-induced cardiomyopathy, arrhythmogenic right ventricular 
cardiomyopathy, infiltrative cardiomyopathy, hypertrophic cardiomyopathy, athletic heart, significant 
primary valvular disease, recent myocarditis (<6 months), or congenital heart disease. Significant 
coronary artery disease was excluded by angiography in 192 (77%) patients, and negative stress imaging 
studies in 23 (9%) patients. The remaining 35 (14%) patients were younger than 40 years of age, had no 
history of angina and ≤1 risk factor for CAD. All patients provided written informed consent. The study 
was approved by the local institutional ethics committee. 
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CMR 
CMR was performed on a 1.5T scanner (Siemens Sonata or Avanto, Erlangen, Germany). A standardised 
protocol was employed for all patients. After routine localizer images, cine images were acquired with a 
balanced steady-state free-precession (SSFP) pulse sequence and retrospective electrocardiographic 
gating during an end-expiratory breath-hold. Cine imaging was first performed in horizontal and vertical 
long-axis planes, followed by acquisition of a stack of contiguous short-axis cines at 10 mm intervals (7 
mm slice thickness with 3 mm gap) from the atrio-ventricular ring to apex. Typical sequence parameters 
were as follows: repetition time 3.2 ms, echo time 1.6 ms, in-plane resolution of 2.1 x 1.3 mm, flip angle 
60º. Late gadolinium enhancement (LGE) images were acquired 10 to 15 minutes after the intravenous 
administration of a gadolinium contrast agent (Gd-DTPA/gadobutrol; Schering, Germany; 0.1mmol/kg) 
using an inversion-recovery gradient echo sequence in identical long-axis and short-axis planes. Inversion 
times were adjusted to null normal myocardium with images repeated in two separate phase-encoding 
directions to exclude artifact.  
 
CMR analysis 
Cine images were analysed using semi-automated software (CMR Tools, Cardiovascular Imaging 
Solutions, London) by a single experienced observer who was blinded to all clinical data. Ventricular 
volumes, ejection fraction and LV mass were measured by standard techniques as previously described.22, 
23 In the case of the right ventricle, this analysis involved 3 principal steps: 1) Delineation of the RV 
endocardial border at end-diastole and end-systole; 2) semi-automated thresholding of the RV blood pool, 
with exclusion of papillary muscles and trabeculae, to determine RV end-diastolic volume (RVEDV) and 
end-systolic volume (RVESV); 3) tracking of the tricuspid valve plane on the horizontal long-axis cine to 
correct for descent of the atrio-ventricular ring during systole.23 Ventricular volumes and LV mass were 
indexed to body surface area. As per recent guidelines, RVSD was defined as RVEF ≤ 45%.24 LGE 
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images were assessed by a second independent blinded observer for the presence of RV or LV myocardial 
fibrosis. Fibrosis was only deemed to be present when the area of midwall LGE could be identified in 
both phase-encoding directions and in two orthogonal views. 
In order to verify the reproducibility and reliability of RV functional assessment by CMR in our cohort, 
the intra- and inter-observer variability were calculated for RVEF measurements in 25 randomly selected 
patients. For intra-observer variability, the RVEF was measured twice by the same observer with a 
minimum interval of two weeks between serial assessments. The inter-observer variability was assessed 
using the measurements obtained by a second independent observer blinded to all other analyses. 
 
Follow-up and end points 
All end points were adjudicated by the consensus of an independent committee blinded to the CMR 
findings. Mortality status was checked at 6-monthly intervals using the National Strategic Tracing Service 
(NSTS), a database for all National Health Service patients in the UK. In the event of death, the 
underlying cause was established from a combination of death certification, post-mortem data where 
available, communication with the patients’ primary care physicians and cardiologists, and review of 
medical records for patients who died in hospital.  
Patients were contacted every 6 months by telephone interview and/or postal questionnaire to document 
the occurrence of non-fatal cardiac events over the follow-up period. This information was substantiated 
by 6-monthly communication with patients’ primary care physician and cardiologist to facilitate review of 
any new correspondence relating to outpatient clinic attendance or hospitalization. Following any hospital 
stay, the medical records were accessed to verify the cause of hospitalization and inpatient course. 
The pre-defined primary end point was a composite of all-cause mortality or cardiac transplantation. Two 
additional secondary end points were pre-specified: a) Cardiovascular mortality (sudden cardiac death, 
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HF, stroke or thromboembolic event) or cardiac transplantation; b) A HF composite of HF death, 
unplanned HF hospitalization or cardiac transplantation. Mode of death was classified according to a 
modified Hinkle-Thaler system.25 Sudden cardiac death was defined as unexpected death either within 1 
hour of cardiac symptoms in the absence of progressive cardiac deterioration, during sleep or within 24 
hours of last being seen alive. HF death was defined as death associated with unstable, progressive 
deterioration of pump function despite active therapy. HF hospitalization was diagnosed in patients 
admitted to hospital with signs and symptoms of decompensated HF requiring treatment with intravenous 
HF medication (diuretics, vasodilators or inotropic agents). Follow-up of patients who underwent cardiac 
transplantation was censored at the time of procedure. Only the first event in each patient was included in 
the outcome analysis. 
 
Statistical analysis 
Baseline characteristics, stratified by the presence (RVSD+) or absence (RVSD-) of RVSD, are expressed 
as frequency (%) for categorical data and mean ±SD for continuous data. Differences between the two 
groups were assessed by the chi-square or Fisher’s exact tests for categorical variables and unpaired 
Student’s t-test for continuous variables. Linear regression analysis was used to model the relationship 
between RVEF and LVEF. Intra-observer and inter-observer variability was assessed using the Bland-
Altman method,26 with results presented as mean differences and 95% limits of agreement. 
The study population was divided into four subgroups based on RVEF value (>60%, 45-60%, 30-45%, 
<30%). Kaplan-Meier survival curves were constructed to estimate the cumulative event rate for each end 
point according to presence or absence of RVSD and RVEF subgroup. Event times were measured from 
the date of CMR study to the index composite event. The log-rank test was used to compare the Kaplan-
Meier survival curves. A univariable Cox proportional-hazards model was employed to analyse the 
relationship between baseline covariables and end points. Results are reported as hazard ratios (HRs) with 
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95% confidence intervals (CIs). In order to identify independent predictors of outcome, forward stepwise 
multivariable Cox regression analysis was performed. Candidate variables with P value < 0.10 on 
univariable analysis were considered for entry and included in the multivariable model if they improved 
the likelihood ratio statistic by an amount which corresponded to a P value of <0.05. For each end point, 
two multivariable models were constructed based on inclusion of either RVSD as a binary categorical 
variable or RVEF subgroup. Receiver operator characteristic (ROC) curves were used to determine the 
optimal prognostic RVEF cut-off value (highest sum of sensitivity and specificity) for the primary end 
point of all cause mortality or cardiac transplantation at 5-years of follow-up. The results for sensitivity, 
specificity, negative predictive value (NPV) and positive predictive value (PPV) are given with their 95% 
confidence intervals. The incremental prognostic value of RVSD for the prediction of the primary end 
point at 5-years, over and above other significant predictors in the multivariable model, was assessed 
using net reclassification improvement. For each patient, the predicted 5-year risk of death/cardiac 
transplantation was determined on the basis of a Cox regression model with and without RVSD. 
Reclassification was examined using 5-year risk thresholds of <5%, 5-10%, 10-20% and ≥20%. All 
analyses were conducted with Stata version 12 (StataCorp, College Station, Texas). A 2-tailed P value of 
<0.05 was considered statistically significant. 
 
RESULTS 
Study population 
The study cohort comprised of 250 patients whose baseline characteristics are summarised in Table 1. 
The mean RVEF for the entire cohort was 48±13%. A total of 86 (34%) patients had RVSD. Compared to 
patients without RVSD, patients with RVSD had higher resting heart rate, lower systolic and diastolic 
blood pressures, more severe New York Heart Association (NYHA) functional class and a lower 
prevalence of left bundle branch block. There was no significant difference in age or gender between 
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groups. At enrolment, patients with RVSD were more likely to receive treatment with beta-blockers, 
angiotensin converting enzyme inhibitors or angiotensin II antagonists, digoxin, loop diuretics and 
aldosterone antagonists. RVSD was also associated with more severe biventricular adverse remodelling, 
with higher indexed ventricular volumes and lower LVEF in the RVSD+ group. On LGE-CMR, no 
patient was observed to have fibrous replacement of the RV free wall. However, LV midwall fibrosis was 
present in 28% of the cohort and was more prevalent in patients with RVSD. A positive correlation was 
observed between RVEF and LVEF measurements (r=0.58; p<0.001) (Figure 1). 
 
Intra-observer and inter-observer variability 
Analysis of both the intra-observer and inter-observer variability showed high levels of agreement for the 
measurement of RVEF. The mean difference (95% limits of agreement) for the intra-observer study was 
0.8% (-4.5, 6.0), whilst for inter-observer study this was 0.7% (-6.6, 5.3). 
 
Primary end point 
Patients were followed up for a median duration of 6.8 years (interquartile range 5.9 to 8.1 years). Data 
were collected for a total of 1640 patient-years of follow-up. During follow-up, 52 patients died and an 
additional 7 patients underwent cardiac transplantation for end-stage heart failure. The primary end point 
of all-cause mortality or cardiac transplantation therefore occurred in 59 (24%) patients (Table 2).  
Figure 2A shows the event-free survival curves of the study population according to the presence or 
absence of RVSD as defined by an RVEF cut-off of 45%.  Patients with RVSD had a significantly higher 
rate of all-cause mortality or cardiac transplantation (P<0.001). Among the 86 patients with RVSD, 42 
(49%) patients reached the primary end point, as compared with only 17 (10%) of the 164 patients 
without RVSD (HR, 5.90; 95% CI, 3.35 to 10.37; P<0.001) (Table 2). Additional significant univariable 
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predictors of the primary end point are listed in table 3. After forward stepwise multivariable analysis, 
RVSD was the most significant independent predictor of all-cause mortality or cardiac transplantation 
(HR, 4.24; 95% CI, 2.31 to 7.78; P<0.001) (Table 3). Other covariables that were found to be 
independently associated with transplant-free overall survival in the multivariable model were diastolic 
blood pressure (HR, 0.97; 95% CI, 0.95 to 1.00; P=0.026), NYHA class (HR, 1.70; 95% CI, 1.18 to 2.44; 
P=0.004), LVEDV index (HR per 10 ml/m2 increment, 1.06; 95% CI, 1.01 to 1.12; P=0.018) and midwall 
fibrosis (HR, 3.27; 95% CI 1.88 to 5.67; P<0.001). RVSD remained a significant independent predictor of 
all-cause mortality alone with patients who underwent cardiac transplantation censored at the time of 
transplant (HR, 4.20; 95% CI, 2.24 to 7.90; P<0.001). 
Kaplan-Meier survival analysis also showed a significant association between RVEF subgroup and the 
primary end point (P<0.001) (Figure 3A). In a multivariable Cox regression model, patients with an 
RVEF<30% (HR, 5.99; 95% CI, 1.33 to 26.95; P=0.020) or between 30-45% (HR, 7.75; 95% CI, 1.82 to 
33.00; P=0.006) had a significantly higher risk of all-cause mortality or cardiac transplantation compared 
to those with an RVEF>60% (Table 3). There was no difference in outcome between patients in the 
RVEF 45-60% or RVEF>60% subgroups (HR, 1.85; 95% CI, 0.41 to 8.29; P=0.420). 
ROC analysis revealed that a cut-off of 45% was the optimal RVEF value for the prediction of all-cause 
mortality or cardiac transplantation at 5-years (Figure 4). At this cut-off the sensitivity was 71% (95% CI, 
56% to 84%), specificity was 74% (95% CI, 67% to 84%), PPV was 37% (95% CI, 27% to 48%) and 
NPV was 92% (95% CI, 87% to 96%) for the primary end point. The area under the ROC curve was 0.72 
(95% CI, 0.65 to 0.80).  
Reclassification of patient risk was assessed following the addition of RVSD to a baseline 5-year risk 
model constructed using the other independent predictors (diastolic blood pressure, NYHA class, LVEDV 
index and midwall fibrosis) identified on multivariable analysis. The addition of RVSD to the baseline 
model resulted in 94 correct (down) reclassifications and 30 incorrect (up) reclassifications among the 
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205 alive/non-transplant patients at 5-years of follow-up (see the online-only Data Supplement). 
Additionally, 9 correct (up) and 9 incorrect (down) reclassifications occurred among the 45 
deceased/transplant patients. The overall net reclassification improvement after adding RVSD to the 
baseline risk model was 0.31 (95% CI, 0.10 to 0.53, P=0.001). 
 
Secondary end points 
Among the 52 deaths during the follow-up period, 43 (83%) were cardiovascular in etiology including 21 
sudden cardiac death, 20 HF deaths and 2 deaths due to stroke or pulmonary embolism (Table 2). Thirty-
nine (16%) patients were hospitalized for the treatment of decompensated HF.  
A total of 50 (20%) patients reached the secondary composite end point of cardiovascular mortality or 
cardiac transplantation (Table 2). The presence of RVSD was associated with significantly worse 
outcome on Kaplan-Meier analysis (P<0.001) (Figure 2B). On multivariable analysis, RVSD was a 
significant and independent predictor of cardiovascular death or transplantation (HR, 3.77; 95% CI, 1.99 
to 7.13; P<0.001), together with diastolic blood pressure (HR, 0.97; 95% CI, 0.94 to 1.00; P=0.022), 
NYHA functional class (HR, 1.70; 95% CI, 1.15 to 2.52; P=0.008), LVEDV index (HR, 1.08; 95% CI, 
1.02 to 1.14; P=0.006) and midwall fibrosis (HR, 4.84; 95% CI 2.62 to 8.93; P<0.001) (Table 4). Kaplan-
Meier estimates of transplant-free cardiovascular survival according to RVEF subgroup are shown in 
Figure 3B. There was a significant difference in the rate of cardiovascular death or transplantation 
between RVEF subgroups (P<0.001). Analysis between groups in the multivariable model revealed that 
this difference was primarily driven by the worse outcome observed in the RVEF<30% and RVEF 30-
45% subgroups (Table 4).  
The secondary HF composite end point of HF death, HF hospitalization or cardiac transplantation 
occurred in 49 (20%) patients (Table 2). Kaplan-Meier analysis revealed a significantly worse event-free 
survival rate among patients with RVSD (P<0.001) (Figure 2C). The multivariable model identified four 
Gulati et al: RV Dysfunction in DCM 
 
 
CIRCULATIONAHA/2013/002518/R13 
 
independent predictors of HF outcome: RVSD (HR, 2.85; 95% CI, 1.45 to 5.61; P=0.002), NYHA 
functional class (HR, 2.49; 95% CI, 1.63 to 3.82; P<0.001), LVESV index (HR per 10ml/m2, 1.11; 95% 
CI, 1.06 to 1.17; P<0.001) and midwall fibrosis (HR, 2.52; 95% CI 1.36 to 4.65; P=0.003) (Table 4). 
Kaplan-Meier curves by RVEF subgroup demonstrated a stepwise increase in the incidence of the HF 
composite with decreasing RVEF (P<0.001) (Figure 3C). After multivariable analysis, the adjusted 
hazard ratios for the HF composite in the RVEF<30%, 30-45% and 45-60% subgroups, as compared with 
the RVEF>60% subgroup, were 9.37 (95% CI, 1.18 to 74.16; P=0.034), 9.35 (95% CI, 1.22 to 71.40); 
P=0.031) and 4.03 (95% CI, 0.52 to 31.10; P=0.182) (Table 4). 
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DISCUSSION 
Risk stratification in DCM is important because of the associated morbidity and mortality due to HF and 
sudden cardiac death.27, 28 Although current risk stratification is primarily guided by the degree of adverse 
LV remodelling, there is increasing appreciation of the potential impact of RVSD on outcome.1, 3, 4 In this 
study, we investigated the prevalence and prognostic significance of RVSD, as identified by CMR, in a 
broad DCM cohort with a wide spectrum of phenotypic severity. Our results indicate that RVSD is 
present in approximately one third of DCM patients, and represents an independent and incremental 
marker of adverse prognosis. After adjustment for established prognosticators including LV parameters 
and NYHA functional class on multivariable analysis, patients with RVSD experienced a four-fold 
increase in all-cause mortality or cardiac transplantation. RVSD was also an independent predictor of 
transplant-free cardiovascular survival and HF outcomes. The assessment of RVSD improved risk 
stratification for transplant-free overall survival. These findings therefore suggest that assessment of 
RVEF, in addition to LV morphological and functional parameters, may further enhance the prognostic 
utility of CMR in DCM.   
A number of imaging indices are available to evaluate RV systolic function. In addition to RVEF, other 
commonly used indices in the clinical arena include the tricuspid annular plane systolic excursion 
(TAPSE), tricuspid annular peak systolic velocity (TAPSV) measured by tissue Doppler imaging, and RV 
fractional area change. Although TAPSE and TAPSV have been shown to correlate reasonably well with 
RVEF,29-31 they are limited to the assessment of longitudinal systolic function,32 dependent on RV loading 
conditions,4 and subject to confounding by significant LV systolic impairment33, 34 and tricuspid 
regurgitation.35 RV fractional area change is derived from a single four-chamber view and may therefore 
be misleading in patients with regional contractile abnormalities.5 In contrast RVEF is more 
representative of global systolic performance. Consequently, although it is itself load-dependent, RVEF 
represents the most widely accepted and clinically validated index of RV contractility.2  
Gulati et al: RV Dysfunction in DCM 
 
 
CIRCULATIONAHA/2013/002518/R15 
 
Accurate estimation of RVEF has historically been very difficult. Established techniques for RVEF 
assessment include transthoracic echocardiography (TTE), thermodilution, contrast or radionuclide 
ventriculography and CMR. Due to its widespread availability, TTE is typically the first line imaging 
technique for RV functional assessment.4, 36 However, quantitative assessment of RVEF by TTE is 
dependent on geometric modelling which is problematic in the case of the right ventricle due to its 
asymmetric crescentic shape, heavily trabeculated endocardial surface and bellows-like contraction 
pattern.2, 20 The substernal location of the right ventricle poses further challenges for imaging by TTE due 
to inadequate acoustic windows and suboptimal visualisation of its anterior wall.32, 37 Both thermodilution 
and contrast ventriculography are invasive, with the latter also limited by the complex RV geometry. The 
clinical application of these catheterization techniques for RV evaluation is therefore limited. Although 
non-invasive and independent of geometric modelling, radionuclide imaging requires exposure to ionizing 
radiation, has low spatial resolution, is susceptible to attenuation artifacts, and does not allow reliable 
delineation of the RV and right atrial cavities.31 
CMR offers several advantages with respect to RV assessment. The multiplanar imaging and three-
dimensional volume acquisition provided by CMR eliminate the need for geometrical assumptions 
regarding RV shape.16, 23 Balanced SSFP cine acquisitions yield high spatial resolution images with 
excellent discrimination between blood and endocardium.23 The high accuracy and reproducibility of 
CMR estimates of RV volumes and EF have been extensively validated, albeit predominantly in healthy 
individuals.15-19 Assessment of the inter-observer and intra-observer variability in RVEF measurement in 
our study population generated comparable reproducibility measures to those reported in normal 
subjects.16-19 Our data therefore confirm the utility of CMR for reliable RVEF measurement in DCM, 
despite the adverse remodelling of the right ventricle which frequently accompanies this condition. 
The normal range of RVEF varies depending on the methodology used for assessment. The accepted 
lower limit of radionuclide-derived RVEF is 40%.38 Studies that have investigated the prognostic 
significance of RVEF measured by catheterization techniques most commonly used a cut-off value of 
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35% to define RVSD.9, 12, 14 There is currently no international consensus regarding normal values for 
RVEF assessed by CMR. In a CMR study of 120 healthy subjects, Maceira et al. found that the lower 
limit of the 95% CI for RVEF varied from 48% to 59 % depending on age and gender.23 In this study we 
defined RVSD according to an RVEF ≤45%, based on the value proposed by the recent modified Task 
Force Criteria for the identification of RVSD by CMR in arrhythmogenic right ventricular 
cardiomyopathy.24 ROC analysis demonstrated that an RVEF of 45% was also the optimal cut-off value 
for predicting the primary end-point of all-cause mortality or cardiac transplantation at 5-years in our 
cohort. Subgroup analysis of patients with RVEF >45%, revealed no significant difference in outcome 
between patients with RVEF 45-60% and those with RVEF>60% for any of the end-points. An RVEF of 
45% would therefore appear to represent a rational threshold for the CMR diagnosis of RVSD, both with 
respect to DCM phenotypic characterisation and risk stratification. 
Although our study did not evaluate the underlying mechanisms of RVSD in DCM, the significant strong 
correlation observed between LVEF and RVEF is consistent with a pathophysiological link between left 
and right ventricular systolic function. LV systolic dysfunction may negatively impact upon RV 
contractility in DCM via multiple mechanisms including increased afterload due to secondary pulmonary 
hypertension, RV involvement from the LV cardiomyopathic process, ventricular interdependence due to 
septal dysfunction and myocardial ischemia secondary to reduced coronary perfusion pressure.1 It has 
therefore been proposed that RVSD may signify a “common final pathway” in HF progression and 
provide a sensitive marker of future decompensation and poor prognosis accordingly.1 
Several previous reports have documented that impaired RVEF is an important prognostic factor in HF.6-9 
However, this observation is based on the study of mixed HF cohorts of ischemic and non-ischemic 
etiology, in which radionuclide ventriculography or thermodilution were used for RVEF measurement. 
The prognostic relevance of RVSD may vary according to HF etiology. In 2006, the National Heart, Lung 
and Blood Institute (NHLBI) identified the study of RV function as a priority in cardiovascular research.1 
CMR represents the current gold standard assessment for RVEF and yet despite the NHLBI’s 
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recommendations, there are no published CMR data regarding the prognostic implications of RVSD in 
either DCM or the general HF population. To the best of our knowledge, the present study is therefore the 
first to show that CMR assessment of RVEF predicts outcome in HF secondary to non-ischemic DCM. 
Our findings complement the few other studies to date that have previously examined the prevalence12 
and prognostic significance13, 14 of RVSD in DCM. La Vecchia et al. found that RVSD was more common 
in patient with DCM versus those with ischemic HF, despite similar levels of LV impairment in the two 
groups.12 In their study, the prevalence of RVSD (defined by an RVEF <35%) in 92 DCM patients was as 
high as 65%, leading the authors to propose that RVSD may represent a marker for DCM. Whilst our data 
confirm that RVSD is relatively common in DCM, it was detected in only 34% of the study population. 
The lower prevalence observed in our cohort, despite using a higher RVEF threshold to define RVSD, 
may be attributed to differences in selection criteria and EF assessment methodology between the two 
studies. La Vecchia only enrolled DCM patients with at least moderate LV impairment at baseline (LVEF 
<45%) and used contrast ventriculography for both LVEF and RVEF measurement. In the present study 
however, CMR was used to confirm DCM diagnosis at entry and assess RVEF thereafter. The high 
fidelity of biventricular parameters assessed by CMR not only facilitates more accurate quantification of 
RVEF, but also allows confident diagnosis of DCM in patients with mild LV dilatation and dysfunction.39 
As a result, our cohort is composed of DCM patients with a wider spectrum of phenotypic severity, 
including those with mild or early disease. 
Only two studies have previously evaluated the prognostic value of RVSD specifically in non-ischemic 
DCM.13, 14 Although both these studies also demonstrated that RVSD was associated with transplant-free 
overall survival, they were performed prior to the widespread incorporation of beta-blockers into standard 
HF therapy, in small DCM cohorts (62 to 85 patients), in which RVEF was measured by invasive 
catheterization techniques. Only one study addressed whether RVSD was an independent predictor of 
outcome using multivariable analysis.13 However, this study did not include midwall fibrosis, another 
important prognosticator in DCM,40-42 in the survival analysis. In contrast we have investigated the 
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prognostic impact of RVSD in a comparatively large cohort of DCM patients, who were accurately 
characterised by LGE-CMR and treated with contemporary HF pharmacological therapy, during a longer 
follow-up. On stepwise multivariable analysis, we have demonstrated that RVSD is not only an important 
predictor of transplant-free overall survival, but also predicts other hard end points including 
cardiovascular mortality or cardiac transplantation, and HF death, HF hospitalization or cardiac 
transplantation. Whilst cardiac transplantation is frequently used as a surrogate for cardiovascular death, 
analysis of overall survival excluding transplantation yielded similar results. The prognostic significance 
of RVSD is independent of established prognosticators, including measures of LV size and function, and 
midwall fibrosis. NRI analysis further revealed that RVSD provided incremental predictive value for 
transplant-free survival, when compared to other independent risk predictors. Identification of RVSD by 
CMR therefore improves risk stratification in DCM and may help guide management decisions relating to 
patient selection and timing for major interventions, such as cardiac transplantation or ventricular assist 
device implantation. 
 
Study Limitations 
The study cohort is selected in that it consists of DCM patients referred for CMR assessment by their 
treating cardiologists. Whilst this may potentially be subject to referral bias, we studied consecutive 
patients with a broad range of phenotypic severity. CMR measurement of RVEF from images acquired in 
the axial orientation may be more reproducible than the short axis orientation used in this study.16 We 
deliberately employed the short axis orientation since this is conventionally used in clinical practice due 
to the fact it allows simultaneous analysis of LV and RV parameters from a single data set. Our results 
additionally revealed good reproducibility with this method. In this study, RVEF was only measured at 
rest. Evaluation of RV contractile reserve may offer additive prognostic information. Due to the limited 
number of events per candidate variable, there is a possibility of overfitting in our multivariate models 
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and further independent validation is needed. Renal function was not systematically recorded at the time 
of CMR assessment in all patients and is therefore not included in our analyses. Similarly, the absence of 
contemporaneous pulmonary arterial pressure measurements means that we were unable to elucidate the 
contribution of pulmonary arterial hypertension to the development of RVSD or outcome. However, 
accurate evaluation of pulmonary arterial pressure requires invasive right heart catheterization as 
estimates derived from Doppler echocardiography are frequently inaccurate.43 It was not deemed ethical 
to perform right heart catheterization in all study patients. Whilst CMR itself is unable to assess 
pulmonary arterial pressure, our study demonstrates that non-invasive assessment of RV function by 
CMR may additionally serve as an important prognostic marker.  
 
Conclusions 
RVSD is common in DCM with a prevalence of 34% in our cohort. Detection of RVSD by CMR 
represents a powerful independent predictor of transplant-free survival and adverse HF outcomes in 
DCM. Routine functional evaluation of the right ventricle is therefore warranted in the CMR examination 
of DCM patients for comprehensive phenotypic characterization and risk stratification. Further study is 
required to evaluate whether amelioration of RVSD, with treatments that target RV performance, may yet 
improve prognosis. 
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TABLE LEGENDS 
 
Table 1. Baseline Characteristics of the Study Group According to the Presence (RVSD+) or 
Absence (RVSD-) of Right Ventricular Systolic Dysfunction. 
Plus-minus values are means ±SD. VF denotes ventricular fibrillation, VT ventricular tachycardia, AF 
atrial fibrillation, DCM dilated cardiomyopathy, LBBB left bundle branch block, NYHA New York Heart 
Association, ACE angiotensin-converting enzyme, ARB angiotensin II-receptor blocker, LV left 
ventricular, RV right ventricular, EDV end-diastolic volume, ESV end-systolic volume, EF ejection 
fraction.  
 
Table 2. Study Outcome Data According to Presence (RVSD+) or Absence (RVSD-) of Right 
Ventricular Systolic Dysfunction. 
CI denotes confidence interval. 
* The number of patients who experienced an index composite outcome is stated. 
 
Table 3. Hazard Ratios for All-Cause Mortality or Cardiac Transplantation in Univariable and 
Multivariable Analyses 
* In multivariable model 1, right ventricular systolic dysfunction (presence or absence) was included as a 
covariable.  
† In multivariable model 2, right ventricular ejection fraction subgroup was included as a covariable. 
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CI denotes confidence interval, VF ventricular fibrillation, VT ventricular tachycardia, AF atrial 
fibrillation, DCM dilated cardiomyopathy, LBBB left bundle branch block, NYHA New York Heart 
Association, ACE angiotensin-converting enzyme, ARB angiotensin II-receptor blocker, LV left 
ventricular, RV right ventricular, EDV end-diastolic volume, ESV end-systolic volume, EF ejection 
fraction, RVSD right ventricular systolic dysfunction. 
 
Table 4. Hazard Ratios for Secondary End Points in Multivariable Analysis 
All baseline covariables with a P<0.05 on univariable analysis were entered into the multivariable model. 
Only those covariables which were selected as independent predictors of outcome on forward stepwise 
multivariable analysis are displayed. 
* In multivariable model 1, right ventricular systolic dysfunction (presence or absence) was included as a 
covariable.  
† In multivariable model 2, right ventricular ejection fraction subgroup was included as a covariable. 
CI denotes confidence interval, NYHA New York Heart Association, LV left ventricular, EDV end-
diastolic volume, ESV end-systolic volume, RVSD right ventricular systolic dysfunction, RVEF ejection 
fraction, HF heart failure. 
Gulati et al: RV Dysfunction in DCM 
 
 
CIRCULATIONAHA/2013/002518/R26 
 
FIGURE LEGENDS 
 
Figure 1. Relationship between Right Ventricular Ejection Fraction (RVEF) and Left Ventricular 
Ejection Fraction (LVEF). The red trace represents the fitted linear regression line. 
 
Figure 2. Kaplan-Meier Estimates of the Time to All-Cause Mortality or Cardiac Transplantation 
(Panel A), Cardiovascular Mortality or Cardiac Transplantation (Panel B), and Heart Failure 
Death, Heart Failure Hospitalization or Cardiac Transplantation (Panel C), According to Presence 
or Absence of Right Ventricular Systolic Dysfunction. A right ventricular ejection fraction cut-off 
value of 45% was used to define right ventricular systolic dysfunction. RVEF denotes right ventricular 
ejection fraction. 
 
Figure 3. Kaplan-Meier Estimates of the Time to All-Cause Mortality or Cardiac Transplantation 
(Panel A), Cardiovascular Mortality or Cardiac Transplantation (Panel B), and Heart Failure 
Death, Heart Failure Hospitalization or Cardiac Transplantation (Panel C), According to Right 
Ventricular Ejection Fraction Subgroup. 
 
Figure 4. Receiver Operating Characteristic Curve for the Overall Performance of Right 
Ventricular Ejection Fraction for the Prediction of All-Cause Mortality or Cardiac Transplantation 
at 5-Years. 
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TABLES  
 
Table 1. 
  All patients RVSD - RVSD +   
Characteristics (N=250) (N=164) (N=86) P value
Age - yr 50.8±14.0 51.9±13.5 48.7±14.6 0.081 
Male sex (%) 171 (68.4) 108 (65.9) 63 (73.3) 0.232 
History of VF or sustained VT (%) 15 (6.0) 9 (5.5) 6 (7.0) 0.638 
History of AF (%) 37 (14.8) 20 (12.2) 17 (19.8) 0.109 
Diabetes (%) 21 (8.4) 13 (7.9) 8 (9.30 0.710 
Smoker (%) 47 (18.8) 27 (16.5) 20 (23.3) 0.192 
History of alcohol excess (%) 32 (12.8) 17 (10.4) 15 (17.4) 0.112 
Family history of DCM (%) 18 (7.2) 15 (9.2) 3 (3.5) 0.100 
Heart rate - beats/min 75.6±14.9 72.4±13.4 81.9±15.7 <0.001 
Systolic blood pressure - mm Hg 119.1±18.9 123.0±17.4 111.6±19.4 <0.001 
Diastolic blood pressure - mm Hg 72.6±11.6 73.9±10.9 70.2±12.6 0.017 
LBBB (%) 66 (26.4) 51 (31.1) 15 (17.4) 0.020 
NYHA functional class (%)         
 I 103 (41.2) 84 (51.2) 19 (22.1) <0.001 
 II 96 (38.4) 63 (38.4) 33 (38.4)   
 III 45 (18.0) 16 (9.8) 29 (33.7)   
 IV 6 (2.4) 1 (0.6) 5 (5.8)   
Medications at baseline (%)         
Aspirin 82 (32.8) 58 (35.4) 24 (27.9) 0.233 
Warfarin 64 (25.6) 28 (17.1) 36 (41.9) <0.001 
Beta-blocker 162 (64.8) 98 (59.8) 64 (74.4) 0.021 
ACE-inhibitor or ARB 231 (92.4) 146 (89.0) 85 (98.8) 0.005 
Amiodarone 26 (10.4) 19 (11.6) 7 (8.1) 0.397 
Digoxin 42 (16.8) 18 (11.0) 24 (27.9) 0.001 
Statin 58 (23.2) 39 (23.8) 19 (22.1) 0.764 
Loop diuretic 128 (51.2) 66 (40.2) 62 (72.1) <0.001 
Aldosterone antagonist 82 (32.8) 38 (23.2) 44 (51.2) <0.001 
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Cardiovascular Magnetic Resonance measurements         
LVEDV index - ml/m2 132.9±43.7 122.7±36.1 152.3±50.2 <0.001 
LVESV index - ml/m2 87.2±45.0 73.4±34.7 113.6±50.5 <0.001 
LV stroke volume - ml 90.6±29.1 97.5±25.3 77.5±31.5 <0.001 
LVEF - % 37.1±13.2 42.2±10.7 27.4±12.1 <0.001 
LV mass index - g/m2 105.3±31.8 98.8±26.1 117.7±37.7 <0.001 
RVEDV index - ml/m2 89.8±26.4 80.8±17.1 107.1±32.0 <0.001 
RVESV index - ml/m2 48.5±25.5 35.4±9.9 73.5±27.6 <0.001 
RV stroke volume - ml 82.0±27.5 90.0±24.6 66.8±26.3 <0.001 
RVEF - % 48.2±13.9 56.6±7.2 32.3±8.9 <0.001 
MIdwall fibrosis (%) 71 (28.4) 39 (23.8) 32 (37.2) 0.025 
RVEF subgroup (%)         
RVEF>60% 49 (20)       
RVEF 45-60% 115 (46)       
RVEF 30-45% 55 (22)       
RVEF<30% 31 (12)       
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Table 2.  
  RVSD -  RVSD + Hazard Ratio   
Outcome (N=164) (N=86 ) (95% CI) P Value
  no. of patients (%)     
Primary end point         
All-cause mortality or cardiac transplantation 17 (10.4) 42 (48.8) 5.90 (3.35 to 10.37) <0.001 
All-cause mortality 16 (9.8) 36 (41.9) 5.51 (3.06 to 9.94) <0.001 
Cardiac transplantation 1 (0.6) 6 (7.0) 13.01 (1.56 to 108.26) 0.018 
          
Secondary end points         
Cardiovascular mortality or cardiac transplantation 15 (9.2) 35 (40.7) 5.62 (3.07 to 10.30) <0.001 
Cardiovascular mortality 14 (8.5) 29 (33.7) 5.12 (2.70 to 9.70) <0.001 
          
Heart failure death, heart failure hospitalization or cardiac transplantation* 13 (7.9) 32 (37.2) 6.13 (3.21 to 11.70) <0.001 
Heart failure death 3 (1.8) 17 (19.8) 14.19 (4.15 to 48.45) <0.001 
Heart failure hospitalization  12 (7.3) 27 (31.4) 5.61 (2.84 to 11.10) <0.001 
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Table 3. 
        Multivariable Analysis 
  Univariable Analysis Model 1*   Model 2† 
  
Unadjusted Hazard 
Ratio     Adjusted Hazard Ratio     Adjusted Hazard Ratio   
Variable (95% CI) P value (95% CI) P value (95% CI) P value 
Age - yr 1.00 (0.98 to 1.02) 0.753             
Male sex  1.33 (0.74 to 2.40) 0.335             
History of VF or sustained VT 0.83 (0.26 to 2.66) 0.755             
History of AF 0.68 (0.31 to 1.50) 0.338             
Diabetes 0.82 (0.33 to 2.06) 0.679             
Smoker 0.74 (0.36 to 1.50) 0.396             
History of alcohol excess  1.41 (0.73 to 2.71) 0.309             
Family history of DCM  1.18 (0.47 to 2.96) 0.719             
Heart rate - beats/min 1.02 (1.01 to 1.04) 0.003             
Systolic blood pressure - mm Hg 0.97 (0.96 to 0.99) <0.001             
Diastolic blood pressure - mm Hg 0.95 (0.93 to 0.98) <0.001    0.97 (0.95 to 1.00)  0.026    0.97 (0.95 to 1.00)  0.027 
LBBB  0.79 (0.43 to 1.44) 0.437             
NYHA functional class 2.39 (1.75 to 3.26) <0.001   1.70 (1.18 to 2.44) 0.004   1.71 (1.20 to 2.44) 0.003 
LVEDV index - per 10ml/m2 1.13 (1.08 to 1.17) <0.001   1.06 (1.01 to 1.12) 0.018   1.07 (1.01 to 1.13) 0.013 
LVESV index - per 10ml/m2 1.14 (1.10 to 1.18) <0.001             
LV stroke volume - per 10ml 0.88 (0.80 to 0.97) 0.008             
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LVEF - % 0.94 (0.92 to 0.96) <0.001             
LV mass index - per 10g/m2 1.14 (1.06 to 1.22) <0.001             
RVEDV index - per 10ml/m2  1.14 (1.05 to 1.25) 0.002             
RVESV index - per 10ml/m2  1.22 (1.13 to 1.31) <0.001             
RV stroke volume - per 10ml 0.84 (0.76 to 0.93) 0.001             
RVEF - % 0.95 (0.93 to 0.97) <0.001             
MIdwall fibrosis presence 3.29 (1.95 to 5.54) <0.001 3.27 (1.88 to 5.67) <0.001 3.20 (1.84 to 5.57) <0.001 
RVSD presence 5.90 (3.35 to 10.37) <0.001   4.24 (2.31 to 7.78) <0.001       
RVEF subgroup                 
RVEF>60% 1.00           1.00 
RVEF 45-60% 1.84 (0.53 to 6.42) 0.337         1.85 (0.41 to 8.29) 0.420 
RVEF 30-45% 8.48 (2.56 to 28.12) <0.001         7.75 (1.82 to 33.00) 0.006 
RVEF<30% 11.39 (3.33 to 38.90) <0.001         5.99 (1.33 to 26.95) 0.020 
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Table 4. 
    Multivariable Analysis 
    Model 1*   Model 2† 
    Adjusted Hazard Ratio Adjusted Hazard Ratio   
Secondary End Point Variable (95% CI) P value (95% CI) P value 
Cardiovascular Mortality or Cardiac Transplantation Diastolic blood pressure - mm Hg  0.97 (0.94 to 1.00)  0.022    0.97 (0.94 to 1.00)  0.023 
  NYHA functional class 1.70 (1.15 to 2.52) 0.008   1.71 (1.16 to 2.51) 0.005 
  LVEDV index - per 10ml/m2 1.08 (1.02 to 1.14) 0.006   1.08 (1.02 to 1.14) 0.005 
  MIdwall fibrosis presence  4.84 (2.62 to 8.93) <0.001   4.76 (2.57 to 8.80)  <0.001  
  RVSD presence 3.77 (1.99 to 7.13) <0.001       
  RVEF subgroup           
  RVEF>60%       1.00   
  RVEF 45-60%       1.58 (0.35 to 7.15) 0.551 
  RVEF 30-45%       5.99 (1.39 to 25.85) 0.016 
  RVEF<30%       4.83 (1.07 to 21.90) 0.041 
              
HF Death, HF Hospitalization or Cardiac Transplantation NYHA functional class 2.49 (1.63 to 3.82) <0.001   2.43 (1.59 to 3.72) <0.001 
  LVESV index - per 10ml/m2 1.11 (1.06 to 1.17) <0.001   1.11 (1.05 to 1.17) <0.001 
  MIdwall fibrosis presence  2.52 (1.36 to 4.65) 0.003   2.44 (1.32 to 4.52)  0.004 
  RVSD presence 2.85 (1.45 to 5.61) 0.002       
  RVEF subgroup           
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  RVEF>60%       1.00   
  RVEF 45-60%       4.03 (0.52 to 31.10) 0.182 
  RVEF 30-45%       9.35 (1.22 to 71.40) 0.031 
  RVEF<30%       9.37 (1.18 to 74.16) 0.034 
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